Healthpeak Properties, Inc.

🇺🇸New York Stock Exchange

Articles

18
Show Summary
Show Bulletpoints
Detailed View
Bullish +65

Healthpeak Properties (NYSE:DOC) Hits New 1-Year High - Time to Buy?

📈 DOC stock hit new 52-week high of $21.91 with volume over 6 million shares.

💰 Q1 EPS beat estimates at $0.45 versus consensus of $0.43.

📈 Revenue grew 7.1% year-over-year to $752.95 million in healthcare real estate.

🎯 FY 2026 guidance set between $1.710-$1.750 EPS aligns with analyst consensus.

🏦 Major institutions including State Street and JPMorgan increased holdings in Q4.

📈 DOC stock hit a new 52-week high of $21.91 during Tuesday trading with volume exceeding 6 million shares.

💰 Q1 earnings beat estimates with $0.45 EPS versus the consensus of $0.43 and revenue of $752.95 million.

📈 Revenue grew 7.1% year-over-year, demonstrating solid top-line performance in the healthcare real estate sector.

🎯 FY 2026 guidance set between $1.710-$1.750 EPS aligns with analyst consensus forecasts of $1.75.

🏦 Major institutions including State Street, JPMorgan, and Fuller & Thaler increased their holdings in Q4.

💸 Company paid a monthly dividend of $0.1017 per share on June 26th with a yield of 5.6%.

📊 Analyst sentiment improved recently with multiple firms raising price targets to the $21.00 level.

🏢 Business model focuses on life science facilities, medical office buildings, and senior housing communities.

📉 Insider Scott R. Bohn sold 10,989 shares in May for a total of $213,736, reducing his stake by 59%.

🏛️ Corporate insiders collectively own only 0.23% of the company's outstanding stock.

Bullish Signals
  • Stock hit new 52-week high of $21.91.
  • EPS of $0.45 beat estimates by $0.02.
  • Revenue of $752.95M exceeded expectations.
  • Year-over-year revenue growth reached 7.1%.
  • Banks raised price targets to $21.00.
Risk Factors
  • Insider Scott R. Bohn reduced holdings by 59% in May.
  • Dividend payout ratio of 381.25% exceeds current earnings.
Bullish Signals
  • Stock price reached a new 52-week high of $21.91, indicating strong market momentum and investor confidence.
  • Quarterly EPS of $0.45 beat analyst consensus estimates by $0.02, signaling operational strength.
  • Revenue of $752.95 million exceeded expectations of $694.59 million, showing robust demand for healthcare assets.
  • Year-over-year revenue growth of 7.1% demonstrates sustainable business expansion in the sector.
  • Multiple major banks including JPMorgan and Royal Bank of Canada raised price targets to $21.00.
  • Significant institutional buying activity with State Street, JPMorgan, and Fuller & Thaler increasing stakes.
  • Strong dividend yield of 5.6% provides attractive income for shareholders despite high payout ratio.
  • Analyst consensus remains stable with an average price target of $19.93 supporting current valuation.
Risk Factors
  • Insider Scott R. Bohn sold a significant portion of his holdings, reducing his position by 59% in May.
  • High dividend payout ratio of 381.25% suggests the company is paying out more than its current earnings generate.
Slightly Bearish -20

Highest-Paying Dividend Stocks in the S&P 500 (2026)

📊 Top 10 S&P 500 stocks yield 6.2% to 9.9%, beating Treasury rates.

🚬 Altria leads with 9.9% yield despite consumer habit headwinds.

🏥 Healthpeak offers 7.2% yield but shares dropped 46% in five years.

💊 Walgreens yields 7.0% while closing 450 stores and cutting jobs.

⛽ Kinder Morgan maintains 6.6% yield with a $3 billion buyback program.

📊 The top 10 highest-yielding S&P 500 stocks range from Altria at 9.9% yield to Pfizer at 6.2%, with many yields exceeding current U.S. 10-year Treasury rates of 4.3%.

🚬 Altria (MO) leads the list with a 9.9% yield and a $3.92 annual dividend, having nearly tripled payouts over the last decade despite facing headwinds from shifting consumer habits.

🏥 Healthpeak Properties (PEAK) offers a 7.2% yield but has underperformed significantly, with shares down 46% in the last five years and dividends reduced from a peak of $2.30 to $1.20.

💊 Walgreens Boots Alliance (WBA) yields 7.0% while struggling with consumer spending declines, leading to a plan to close 450 stores and cut 10% of its workforce.

🛡️ 3M (MMM) trades at a 6.9% yield after a 56.5% drop over five years, recently raising its quarterly dividend by a penny while spinning off its healthcare division as Solventum.

⛽ Kinder Morgan (KMI) maintains a 6.6% yield with an active $3 billion buyback program and has increased dividends annually, though it operates heavily in the volatile energy sector.

📡 AT&T (T) and Verizon (VZ) both offer 6.6% yields; AT&T faces risks from its failed Time Warner acquisition, while Verizon is highlighted as a reliable long-term holding with 5G exposure.

🛢️ Devon Energy (DVN) provides a 6.4% yield tied to oil prices, currently facing production weakness until summer seasonality improves cash flows for its fixed-plus-variable dividend strategy.

🏠 Whirlpool (WHR) yields 6.4% with a long history of rising dividends, yet shares have fallen over 24% in five years, resulting in only 0.9% annualized returns over a decade.

💉 Pfizer (PFE) rounds out the list at 6.2% yield; while a reliable payer since the Great Financial Crisis, its stock has declined more than 50% since late 2022.

Bullish Signals
  • Altria tripled dividends over 10 years; recent payout is $3.92.
  • Kinder Morgan raised dividends annually and spent $522M on buybacks.
  • Verizon offers IOT and 5G growth exposure as a dividend stalwart.
  • Devon Energy uses fixed plus variable strategy returning free cash flow.
  • Whirlpool increased dividend from $1.20 in 1995 to $7 today.
Risk Factors
  • High-yield stocks included due to significant underperformance and share price declines.
  • Healthpeak dividend cut from $2.30 peak in 2016 down to $1.20.
  • Walgreens closing 450 stores and reducing workforce by 10%.
  • 3M shares down 56.5% with worst selloff in five years.
  • Whirlpool trading at early 2013 levels with 0.9% annual yield.
  • Pfizer fallen over 50% since end of 2022.
Bullish Signals
  • Altria has nearly tripled its dividend payouts over the last 10 years and recently raised its annual dividend to $3.92 per share.
  • Kinder Morgan maintains a standard practice of annual dividend hikes and has spent $522 million on buybacks in 2023 alone.
  • Verizon is described as a 'dividend stalwart' offering exposure to the growth of the Internet of Things (IOT) and 5G networks.
  • Devon Energy utilizes a 'fixed plus variable' dividend strategy that returns free cash flow from its portfolio properties directly to shareholders.
  • Whirlpool has increased its annual dividend payout from $1.20 in 1995 to $7 today, with the last increase occurring in early 2022.
Risk Factors
  • Many high-yield stocks on the list are included due to significant underperformance and share price declines rather than strong growth prospects.
  • Healthpeak Properties has seen its annual dividend cut from a peak of $2.30 in 2016 down to $1.20 per share since 2021.
  • Walgreens Boots Alliance is closing 450 stores and reducing its workforce by 10% due to muted consumer spending and the end of the COVID vaccine push.
  • 3M issued soft guidance for 2024 profits, contributing to a worst selloff in five years with shares down 56.5% over that period.
  • Devon Energy expects production weakness in the next few quarters until summer seasonality kicks in later this year.
  • Whirlpool shares are trading at levels last seen in early 2013, and a 10-year investment would have yielded only 0.9% annually even with dividends reinvested.
  • Pfizer has fallen more than 50% since the end of 2022 and is trading at valuation levels not seen since 1997.
Slightly Bullish +15

Healthpeak Properties (DOC) Stock After 31% Year-To-Date Rise Is Price Getting Ahead Of Itself - simplywall.st

📈 Shares surged 31% YTD, trading near $21.23.

💰 DCF model values stock at $34.62 intrinsic price.

📉 P/E ratio of 66x exceeds industry average of 20x.

⚠️ Bearish risks include tenant issues and geographic concentration.

🤖 AI management and aging population drive bullish growth.

📈 Healthpeak Properties (DOC) shares have surged 31% year-to-date, trading at approximately $21.23.

💰 A Discounted Cash Flow model estimates an intrinsic value of $34.62, implying a 38.7% discount to current price.

📉 The stock trades at a P/E ratio of 66.0x, significantly higher than the industry average of 20.0x and peer average of 43.0x.

⚖️ Simply Wall St's proprietary Fair Ratio suggests a reasonable P/E of 28.6x, indicating a potential 24.9% premium to fair value.

🤖 Bullish narrative cites AI-driven property management and an aging population driving demand for senior housing.

⚠️ Bearish narrative highlights tenant risk in life science properties and geographic concentration as key concerns.

📊 The latest twelve-month free cash flow is reported at $1.29 billion.

🏥 DOC owns, operates, and develops high-quality real estate focused on healthcare discovery and delivery in the U.S.

Bullish Signals
  • DCF model implies $34.62 intrinsic value, a 38.7% discount.
  • Latest twelve-month free cash flow reached $1.29 billion.
  • Senior housing exposure supports long-term growth from aging population.
  • AI upgrades expected to improve operational efficiency and retention.
Risk Factors
  • Stock trades at 66.0x P/E, triple the 20.0x industry average.
  • Price is a 24.9% premium to fair value per analysis.
  • Tenant risk exists in life science properties from small biotechs.
Bullish Signals
  • The Discounted Cash Flow model estimates an intrinsic value of $34.62 per share, implying a 38.7% discount to the current trading price of $21.23.
  • The company reports strong recent cash generation with latest twelve-month free cash flow at $1.29 billion.
  • Bullish investor narratives highlight long-term support from senior housing exposure and outpatient medical facilities tied to an aging U.S. population.
  • Operational efficiency is expected to improve through AI-driven property management and technology upgrades aimed at enhancing tenant retention.
Risk Factors
  • The stock trades at a P/E ratio of 66.0x, which is more than three times the industry average of 20.0x for Health Care REITs.
  • Simply Wall St's proprietary Fair Ratio analysis suggests the current price represents a 24.9% premium to fair value based on a target P/E of 28.6x.
  • Bearish narratives point to significant tenant risk in life science properties, particularly from smaller biotech companies reliant on capital markets.
Bullish +75

Healthpeak Properties: This 6% Yielding REIT Has More Room To Run

📈 Combines value, income, and recovery potential in healthcare real estate.

🏥 Outpatient medical segments show improving occupancy and strong lease spreads.

💰 Janus Living spin-off unlocks senior housing value while retaining 82% ownership.

📉 Stock trades at 11.2x forward P/FFO, below historical averages.

🏦 Maintains BBB+ balance sheet with a current yield of 6.2%.

📈 Healthpeak Properties combines value, income, and recovery potential in the healthcare real estate sector.

🏥 Outpatient medical and life sciences segments show improving occupancy and strong lease spreads.

💰 The Janus Living spin-off unlocks senior housing value while DOC retains 82% ownership.

📉 Stock trades at 11.2x forward P/FFO, significantly below historical averages.

🏦 Company maintains a BBB+ balance sheet with a current yield of 6.2%.

Bullish Signals
  • 6.2% dividend yield offers attractive income.
  • BBB+ credit rating indicates financial stability.
  • Core medical segments driving revenue growth.
  • Lease escalators provide predictable cash flow.
  • Janus Living spin-off creates value.
Bullish Signals
  • DOC offers a high dividend yield of 6.2%, providing attractive income to investors.
  • The company possesses a strong BBB+ credit rating, indicating financial stability.
  • Occupancy rates and lease spreads in core medical segments are improving, driving revenue growth.
  • Rent escalators embedded in leases provide predictable future cash flow growth.
  • The Janus Living spin-off creates value by allowing Healthpeak to benefit from high-growth senior housing while retaining majority control.
Bullish +65

Healthpeak Properties Stock (US42226K1051): analyst upgrade and ex-dividend date put income REIT in - AD HOC NEWS

📈 BMO raised price target to $24 with 'Outperform' rating.

💰 Stock trades ex-dividend today with $0.102 monthly payout.

📊 Forward dividend yield is approximately 7.1% at current prices.

🏢 Resources Management Corp increased stake by 1,129% in Q4.

🏥 Portfolio includes medical office buildings and senior care assets.

📈 BMO Capital raised Healthpeak's price target to $24 from $20 while reiterating an 'Outperform' rating.

💰 The stock is trading ex-dividend today with a monthly payout of $0.102 per share.

📊 Healthpeak offers a forward dividend yield of approximately 7.1% at current price levels.

🏢 Resources Management Corp CT ADV increased its stake by roughly 1,129% in Q4 to hold ~86,220 shares.

🌍 The company owns and manages healthcare discovery and delivery properties across the US.

📉 MarketBeat data shows a broader analyst consensus average target of $19.54.

📈 Recent performance figures indicate a gain of roughly 28% over a longer comparative period.

🏥 Portfolio includes medical office buildings, life science facilities, and senior care assets.

📅 The stock is listed on the NYSE under the ticker DOC with CUSIP US42226K1051.

Bullish Signals
  • Price target $24 implies mid-teens upside from $20.69.
  • Maintains 'Outperform' rating vs market consensus 'Hold'.
  • Institutional position increased over 1,100% in Q4.
  • Forward dividend yield of approximately 7.1% monthly.
  • Long-term leases with hospital systems and physician groups.
Risk Factors
  • Analyst consensus target of $19.54 is lower than BMO's $24.
  • Healthcare REITs face regulatory and reimbursement risks impacting cash flows.
  • 7.1% yield fluctuates with share price changes and is not guaranteed.
Bullish Signals
  • BMO Capital upgraded the price target to $24, implying mid-teens percentage upside from the recent closing price of $20.69.
  • The company maintains a strong 'Outperform' rating despite a broader market consensus that leans towards a 'Hold'.
  • Resources Management Corp CT ADV demonstrated significant conviction by increasing its position by over 1,100% in Q4.
  • Healthpeak offers an attractive forward dividend yield of approximately 7.1% with monthly distribution frequency.
  • The portfolio focuses on long-term leases with hospital systems and physician groups, providing visibility on rental income.
Risk Factors
  • The broader analyst consensus average price target is $19.54, which is lower than BMO's new target of $24.
  • Healthcare REITs face exposure to sector-specific regulatory and reimbursement risks that could impact cash flows.
  • Yield calculations fluctuate with share price changes, meaning the 7.1% yield is not guaranteed to remain constant.
Somewhat Bullish +50

Healthpeak Properties Gains 22.7% Year to Date: Will the Trend Last?

📈 DOC shares gained 22.7% YTD, outperforming the healthcare real estate sector.

🏥 Q1 2026 occupancy reached 77.7% with strong lab and medical leasing.

💰 Janus Living drove 35% revenue growth and $267M in liquidity proceeds.

📈 Healthpeak Properties (DOC) shares have gained 22.7% year-to-date, significantly outperforming the healthcare real estate industry's 12.7% gain.

🏥 The company is strategically focusing on lab, outpatient medical, and life plan assets in high-barrier markets to drive growth.

🔬 In Q1 2026, Healthpeak executed 141,000 square feet of lab leases with 92% tied to new leasing, raising total occupancy to 77.7%.

🏥 The outpatient medical segment achieved nearly 1.1 million square feet in leases and maintained 91% total occupancy with strong tenant retention.

👴 Janus Living, the senior housing platform, reported a 35% year-over-year revenue growth and 42% adjusted EBITDA expansion in Q1 2026.

💰 The company generated $267 million in proceeds from dispositions and recapitalizations to fund focused growth and enhance liquidity.

📉 Net debt-to-EBITDA stood at 5.4x at the end of Q1 2026, while cash and equivalents rose to $1.17 billion following the Janus Living IPO.

🏦 Healthpeak maintains strong credit ratings of Baa1 from Moody's and BBB+ from S&P Global as of May 4, 2026.

📉 Management is using structured transactions to maintain investment flexibility across different economic cycles.

⚠️ Risks include competition from other healthcare services players, rising construction costs, and a substantial debt burden.

🏆 DOC carries a Zacks Rank #3 (Hold), while competitors like American Tower (AMT) and Lamar Advertising (LAMR) hold higher Buy ratings.

📊 The article notes that anything related to earnings presented represents Funds From Operations (FFO), a key metric for REITs.

Bullish Signals
  • DOC shares gained 22.7% YTD vs 12.7% industry.
  • Executed 141k sq ft lab leases; occupancy rose to 77.7%.
  • Outpatient segment achieved 5.4% cash re-leasing spreads and 91% occupancy.
  • Janus Living revenue grew 35%; adjusted EBITDA expanded 42%.
  • Senior housing same-store NOI grew 13.8% year over year.
  • Generated $267M proceeds to fund growth while maintaining flexibility.
  • Cash rose to $1.17B following Janus Living IPO proceeds.
  • Maintained Baa1 and BBB+ credit ratings as of May 4, 2026.
Risk Factors
  • Healthpeak faces competition from other healthcare industry players.
  • Substantial debt burden worsens Healthpeak's financial situation.
Bullish Signals
  • Shares of Healthpeak Properties (DOC) have gained 22.7% year-to-date, significantly outperforming the industry's upside of 12.7%.
  • The company executed 141,000 square feet of lab leases in Q1 2026, with 92% tied to new leasing and total lab occupancy rising to 77.7% from 77% at year-end 2025.
  • Outpatient medical segment achieved 5.4% cash re-leasing spreads on renewals, ended Q1 2026 at 91% total occupancy, and reported a larger pipeline under letter of intent (LOI).
  • Janus Living reported year-over-year revenue growth of 35% and adjusted EBITDA expansion of 42% for the first quarter of 2026.
  • Senior housing same-store cash net operating income (NOI) grew 13.8% year over year in Q1 2026, reflecting stronger operating performance.
  • Healthpeak generated $267 million in proceeds from recapitalizations, dispositions, and loan repayments in Q1 2026 to fund focused growth while maintaining investment flexibility.
  • Cash and cash equivalents rose to $1.17 billion from $467.5 million in the last quarter following Janus Living IPO proceeds.
  • The company maintained strong long-term credit ratings of Baa1 from Moody's and BBB+ from S&P Global as of May 4, 2026.
Risk Factors
  • Competition from other industry players in the healthcare services sector is explicitly identified as a key concern for Healthpeak.
  • The article states that substantial debt burden adds to the company's woes.
Bullish +75

Healthpeak Properties Gains 22.7% Year to Date: Will the Trend Last?

📈 Shares gained 22.7% YTD, outperforming the industry's 12.7% rise.

🏥 Janus Living drove growth with 35% revenue and 42% EBITDA expansion.

💰 Company raised $267M via dispositions to fund strategic asset growth.

📈 Healthpeak Properties (DOC) shares have gained 22.7% year-to-date, significantly outperforming the industry's 12.7% upside.

⚖️ The stock carries a Zacks Rank #3 (Hold), while management is strategically positioning toward lab, outpatient medical, and life plan assets in high-barrier markets.

🏥 Strong leasing momentum and rising occupancy are driving growth, particularly within the senior housing platform known as Janus Living.

🧪 In the lab segment, Healthpeak executed 141,000 square feet of leases in Q1 2026 with total occupancy reaching 77.7%.

🏥 The outpatient medical segment achieved nearly 1.1 million square feet of leases and maintained 91% total occupancy as of Q1 2026.

👴 Janus Living reported a 35% year-over-year revenue growth and a 42% expansion in adjusted EBITDA for the first quarter of 2026.

💰 The company generated $267 million in proceeds from recapitalizations and dispositions to fund focused growth while enhancing liquidity.

📉 Net debt-to-EBITDA stood at 5.4x at the end of Q1 2026, with cash and equivalents rising to $1.17 billion following Janus Living IPO proceeds.

🏦 Healthpeak maintains long-term credit ratings of Baa1 from Moody's and BBB+ from S&P Global as of May 4, 2026.

📉 The company increased financial flexibility by adding a new $400 million unsecured delayed-draw term loan.

⚠️ Risks include competition from other healthcare services players, rising construction costs, and the substantial debt burden.

🔍 Management expects year-end 2026 lab occupancy to be higher than the 2025 level despite current market conditions.

📈 The outpatient segment achieved 5.4% cash re-leasing spreads on renewals with a robust pipeline under letter of intent (LOI).

🏢 Healthpeak continues to use structured transactions to maintain investment flexibility across different economic cycles.

📊 FFO is the primary metric used to gauge performance for this REIT, as noted in the financial analysis section.

Bullish Signals
  • DOC shares gained 22.7% YTD vs 12.7% industry.
  • Strong leasing momentum drives lab and outpatient growth.
  • Q1 2026 lab occupancy reached 77.7% with new leases.
  • Outpatient medical achieved 91% occupancy and 5.4% spreads.
  • Janus Living revenue grew 35% in Q1 2026.
  • Senior housing NOI expanded 13.8% year over year.
  • Company raised $267M for focused growth initiatives.
  • Liquidity boosted to $1.17B following Janus IPO.
  • Credit ratings remain Baa1 and BBB+ as of May.
Risk Factors
  • Healthpeak faces competition from other healthcare industry players.
  • Substantial debt burden worsens Healthpeak's financial situation.
Bullish Signals
  • Shares of Healthpeak Properties (DOC) have gained 22.7% year-to-date, significantly outperforming the industry's upside of 12.7%.
  • The company is strategically positioning toward lab, outpatient medical, and life plan assets in high-barrier markets driven by strong leasing momentum and rising occupancy.
  • In the first quarter of 2026, Healthpeak executed 141,000 square feet of lab leases with 92% tied to new leasing, pushing total lab occupancy to 77.7%.
  • Management expects year-end 2026 lab occupancy to be higher than the 2025 level, indicating continued growth potential in this segment.
  • The outpatient medical segment achieved 5.4% cash re-leasing spreads on renewals and ended the quarter at 91% total occupancy with 79% tenant retention.
  • Healthpeak's senior housing platform, Janus Living, reported year-over-year revenue growth of 35% and adjusted EBITDA expansion of 42% for the first quarter of 2026.
  • Senior housing same-store cash net operating income (NOI) grew 13.8% year over year in the first quarter of 2026, reflecting stronger operating performance.
  • The company generated $267 million of proceeds from recapitalizations, dispositions, and loan repayments in the first quarter of 2026 to fund focused growth.
  • Cash and cash equivalents rose to $1.17 billion from $467.5 million in the last quarter following Janus Living IPO proceeds, bolstering near-term liquidity.
  • Healthpeak maintained strong long-term credit ratings of Baa1 from Moody's and BBB+ from S&P Global as of May 4, 2026.
Risk Factors
  • Competition from other industry players in the healthcare services sector is explicitly identified as a key concern for Healthpeak.
  • The article states that substantial debt burden adds to the company's woes.
Somewhat Bullish +45

Monthly Dividend Stock In Focus: Healthpeak Properties - Sure Dividend

📈 Q1 revenue surged 7.1% to $753M, significantly beating analyst estimates.

🏥 Portfolio includes 689 healthcare properties with strong occupancy across segments.

💰 FFO beat estimates by $0.02 despite a projected earnings decline.

⚠️ Dividend was cut recently due to pandemic impacts and high interest costs.

📄 This article focuses on Healthpeak Properties (DOC), a monthly dividend stock that switched to this payout schedule in April 2025.

💰 The company posted strong first quarter earnings with Funds-from-Operations per share of $0.45, beating estimates by two cents.

🏢 Healthpeak is the largest healthcare REIT in the U.S., managing 689 properties across life science, senior housing, and medical offices.

📉 FFO had declined for six consecutive years until 2022, but asset sales and debt reduction have led to credit rating upgrades from major agencies.

📈 Revenue increased by 7.1% year-over-year in Q1 to $753 million, significantly beating analyst estimates by $60 million.

🔒 The trust acquired the Gateway campus in San Francisco at a fraction of replacement cost with strong lease signing progress.

🚀 Senior housing business completed an IPO in March 2026, with proceeds expected to add approximately four cents to earnings this year.

🛒 Healthpeak has closed over $700 million in acquisitions and bought back $100 million of stock at a yield of 10% or higher.

🏥 Outpatient Medical facilities finished Q1 with 91% occupancy, while Lab properties ended the quarter at 77.7% total occupancy.

👵 Demographic trends favor the company, as the U.S. senior population is expected to grow significantly with rising life expectancy.

💸 Healthcare spending in the U.S. is projected to grow by about 5% annually through 2030 due to an aging baby boomer generation.

⚠️ The REIT cut its dividend by -19% in 2021 due to pandemic impacts and previously experienced a second dividend cut in the last decade.

📉 Interest expense has doubled since 2021 driven by high interest rates and the acquisition of Physicians Realty Trust.

💹 Despite recent headwinds, the payout ratio remains steady at around 70% of earnings based on adjusted FFO.

👀 Analysts expect earnings of $1.72 per share in 2026 on an adjusted basis, representing a decline from last year's $1.84.

💰 The trust now expects FFO guidance between $1.70 and $1.74 per share, raising the range by two cents from prior expectations.

Bullish Signals
  • Healthpeak (DOC) switched to monthly dividends in April 2025.
  • SECURED upgrades to BBB+ and Baa1 ratings after debt reduction.
  • Q1 FFO per-share reached 45 cents, beating estimates by $0.02.
  • Revenue jumped 7.1% YoY to $753M, exceeding estimates by $60M.
  • Management raised full-year FFO guidance from $1.70-$1.74 per share.
  • Bought back $100M stock at a 10%+ FFO yield.
  • Expected 5% annual U.S. healthcare spending growth until 2030.
  • Senior housing IPO in March 2026 expected to add $0.04 EPS.
  • Outpatient facilities finished quarter at 91% occupancy and 79% retention.
Risk Factors
  • Declining FFO for six consecutive years until 2022.
  • Credit ratings previously downgraded before reaching BBB+ status.
  • Restructuring burdens expected to limit near-term flexibility.
  • Analysts project $1.72 EPS in 2026, below last year's $1.84.
  • Dividend cut -19% in 2021 signals economic vulnerability.
  • Interest expense doubled since 2021 due to rates and merger.
  • Modest 3% annual growth trajectory rather than rapid expansion.
  • Sole reliance on private-pay sources creates spending risk.
Bullish Signals
  • Healthpeak Properties (DOC) has successfully switched to a monthly dividend payout schedule in April 2025, offering more frequent payouts that enhance its appeal for income investors.
  • The REIT secured credit rating upgrades to BBB+ from S&P and Fitch, as well as Baa1 from Moody's following significant asset sales and debt reduction efforts.
  • First quarter earnings demonstrated strong performance with Funds-from-operations per-share of 45 cents, beating analyst estimates by two cents.
  • Revenue jumped 7.1% year-over-year to $753 million, significantly exceeding estimates by a staggering $60 million.
  • Management raised full-year FFO guidance from $1.70-$1.74 per share, up two cents on both ends of the range, reflecting confidence in future prospects.
  • The company recently bought back $100 million of stock at a 10%+ FFO yield, signaling that management believes the shares are undervalued.
  • Healthpeak is well-positioned to benefit from favorable secular trends, including an expected 5% annual growth in the U.S. healthcare spending until 2030.
  • The senior housing business IPO in March 2026 is expected to add approximately four cents to earnings-per-share for the current year.
  • Outpatient Medical facilities finished the quarter at a strong 91% total occupancy with healthy tenant retention of 79%.
Risk Factors
  • Healthpeak Properties posted declining Funds from Operations (FFO) for six consecutive years until 2022, indicating a prolonged period of financial weakness.
  • Despite recent upgrades, the REIT was previously downgraded or struggled with credit ratings before reaching BBB+ and Baa1 status.
  • The restructuring process is expected to continue burdening the company in the near future, potentially limiting immediate operational flexibility.
  • Analysts expect earnings of $1.72 per-share for 2026, which would be meaningfully worse than last year's $1.84 if realized.
  • The REIT cut its dividend by -19% in 2021 due to pandemic impacts, and this was the second dividend cut in the last decade, signaling vulnerability to economic downturns.
  • Interest expense has doubled since 2021 due to high interest rates and the Physicians Realty Trust merger, increasing operational costs.
  • While growth is expected at 3% annually, this represents a modest expansion trajectory rather than rapid growth.
  • The company operates solely on private-pay sources which may expose it to risks if consumer spending or affordability changes in healthcare.
Very Bullish +80

National Healthcare Properties reports that SHOP momentum continues

📈 Q1 results showed strong occupancy momentum and margin expansion across the portfolio.

🤝 NHP partnered with Discovery Senior Living to purchase 13 communities plus options for 13 more.

💼 The SHOP platform grew to 37 communities while shedding 86 outpatient medical facilities.

📈 National Healthcare Properties reported exceptional first-quarter results with continued momentum in occupancy, rate, and margin expansions.

🤝 The company announced a joint venture with Discovery Senior Living to purchase 13 communities, plus an option for 13 more.

📍 NHP has signed agreements to acquire two additional communities—one in Oregon and one in Florida—expected to close in the second or third quarter.

💼 The REIT holds $40.3 million worth of SHOP transactions under letters of intent with an active acquisition pipeline.

🔄 Management is intentionally reorienting its portfolio toward senior living following a May agreement to sell 86 outpatient medical facilities.

🏘️ The company's Senior Healthcare Operations Platform (SHOP) currently comprises 37 communities across 12 states.

📊 First-quarter average SHOP occupancy reached 83.8%, with assisted living improving 490 basis points and memory care advancing 630 basis points.

🚀 CEO Michael Anderson described the completion of the company's initial public offering as a defining moment that raised approximately $531 million in gross proceeds.

⏳ NHP had begun preparing for its listing in late 2024 and early 2025 after internalizing management from its previous name, Healthcare Trust.

📜 The REIT aims to be one of only two publicly traded healthcare REITs where 100% of the senior housing portfolio operates under RIDEA structures rather than net leases.

🚀 Janus Living is cited as the other publicly traded REIT with a RIDEA-only model, having raised $878 million upon its March IPO.

Bullish Signals
  • Occupancy and margin expansions drove exceptional first-quarter results.
  • Agreements signed for Oregon and Florida communities to close in H2.
  • First-quarter total average SHOP occupancy reached 83.8%.
  • Assisted living occupancy improved 490 bps; memory care led at 85.1%.
  • IPO closed in Q1 raising approximately $531 million in gross proceeds.
  • NHP has additional $40.3M of SHOP transactions under signed LOIs.
  • NHP aims to be one of two REITs with 100% RIDEA structure.
Risk Factors
  • Sold 86 outpatient facilities, risking recurring revenue loss.
  • Raised $40.3M less than competitor Janus Living.
  • 100% RIDEA structure creates concentrated operational exposure.
  • Janus IPO saw limited appetite with only 48.3M shares sold.
Bullish Signals
  • National Healthcare Properties' senior housing operating portfolio delivered exceptional results in the first quarter with momentum across occupancy, rate, and margin expansions.
  • The company entered agreements to buy an Oregon assisted living community and a Florida memory care community, with deals expected to close in the second or third quarter.
  • First-quarter total average SHOP occupancy reached 83.8%, with same-store average occupancy also at 83.8%.
  • Assisted living occupancy improved 490 basis points to 85.1%, while memory care led the segment by advancing 630 basis points to 85.1%.
  • The REIT successfully closed its initial public offering in the first quarter, raising approximately $531 million in gross proceeds.
  • NHP has an additional $40.3 million of SHOP transactions under signed letters of intent and maintains an active acquisition pipeline.
  • By internalizing management, NHP plans to be one of only two publicly traded healthcare REITs with 100% of its senior housing portfolio operated under RIDEA structures.
Risk Factors
  • The company sold a portfolio of 86 outpatient medical facilities in May, signaling an intentional reorientation away from that asset class and a potential loss of recurring revenue streams.
  • NHP's initial public offering raised approximately $40.3 million less than the $571 million raised by competitor Janus Living, which could impact market perception or capital raising efficiency.
  • The REIT plans to list as one of only two publicly traded healthcare REITs with 100% of its senior housing portfolio under RIDEA structures, implying a concentrated risk model where none of the communities are net leased, potentially increasing operational exposure for NHP compared to traditional triple-net models.
  • Only 48.3 million shares were sold by Janus Living during its IPO, which may indicate limited market appetite or valuation pressure in this specific niche compared to larger offerings.
Bullish +75

Healthpeak Properties stock (US42226K1051): Hits 52-week high on analyst upgrades - AD HOC NEWS

📈 Shares surged to a 52-week high of $19.91 amid rising analyst price targets.

💰 Earnings beat estimates with quarterly EPS at $0.45 and revenue up 7.1%.

🏥 Diversified healthcare portfolio provides stable cash flow from long-term leases.

🛡️ Aging demographics and defensive asset class status support investment appeal.

⚖️ Despite upgrades, consensus rating remains Hold with a target near $18.75.

📈 Healthpeak Properties shares hit a 52-week high of $19.91 during mid-day trading on Thursday, May 14, 2026.

📊 UBS Group raised its price target from $17 to $19 while maintaining a neutral rating after the recent surge.

🚀 Robert W. Baird increased its price target from $19 to $21 with an outperform rating issued on May 13.

🏦 Citigroup lifted its objective from $17.50 to $20, also keeping a neutral rating as of May 12.

💰 In the most recent quarter, earnings per share reached $0.45, beating consensus estimates of $0.43.

📈 Quarterly revenue grew by 7.1% year-over-year according to financial disclosures referenced on MarketBeat.

🏥 The company owns and operates a diversified portfolio focused on life science, medical office, and post-acute care facilities.

💼 Revenue is primarily generated through long-term leases to healthcare operators, research institutions, and medical providers.

📉 Demographic trends such as an aging population are backing stable cash flows for the REIT.

🔬 Expansion in high-demand life science assets benefits from biotech innovation hubs in key US markets.

💸 The stock offers a dividend yield of approximately 6.14% appealing to income-focused investors.

🛡️ Healthcare real estate is viewed as a defensive asset class tied to the $4 trillion US healthcare economy.

📉 Despite recent upgrades, the consensus analyst rating remains a Hold with an average price target of $18.75.

Bullish Signals
  • Shares hit 52-week high at $19.91.
  • Multiple analysts raised price targets.
  • EPS beat estimates at $0.45.
  • Revenue grew 7.1% year-over-year.
  • Dividend yield approximates 6.14%.
  • Tied to $4 trillion healthcare economy.
Risk Factors
  • Analyst target $18.75 is below current price.
  • UBS maintains neutral rating, missing buy call.
  • Baird ignores biotech hub funding risk concerns.
Bullish Signals
  • Healthpeak Properties shares reached a new 52-week high of $19.91 on NYSE following multiple analyst upgrades.
  • UBS Group raised its price target from $17.00 to $19.00, Robert W. Baird lifted its target from $19.00 to $21.00 with an outperform rating, and Citigroup increased its objective from $17.50 to $20.00.
  • In the most recent quarter, the company achieved earnings per share of $0.45, surpassing consensus estimates of $0.43, demonstrating strong operational performance.
  • Quarterly revenue grew 7.1% year-over-year, indicating robust demand for the company's diversified healthcare real estate portfolio.
  • The REIT benefits from resilient demand in a growing sector tied to the $4 trillion US healthcare economy driven by demographic trends like aging populations.
  • Healthpeak Properties offers a defensive investment opportunity with an attractive dividend yield of around 6.14% as of recent trading data.
Risk Factors
  • Despite the stock hitting a 52-week high of $19.91, the consensus analyst rating remains 'Hold' with an average price target of $18.75, which is below the current trading price.
  • The UBS Group upgrade maintained a neutral rating rather than improving its outlook to buy or outperform, suggesting only moderate positive sentiment from major banks.
  • Robert W. Baird's upgrade cited strong leasing activity in life sciences but did not mention any specific risks regarding biotech innovation hubs which could face funding constraints.
Somewhat Bullish +50

Healthpeak Properties Boosts Guidance After Strong Q1 Results

Healthpeak reported Q1 2026 net income of $0.28/share with strong leasing activity.

Affiliate IPO raised $880M, boosting FY 2026 earnings guidance to $0.45 FFO.

Analysts maintain Buy ratings despite lab decline and mixed same-store NOI growth.

📈 Healthpeak Properties reported strong Q1 2026 results with net income of $0.28 per share and FFO (Adjusted) of $0.45 per share.

🏢 The company experienced robust leasing activity within its outpatient medical and laboratory portfolios.

💰 Janus Living, a majority-owned affiliate, completed an oversubscribed IPO in March 2026, raising approximately $880 million.

🚀 This capital raise has led Healthpeak to increase its 2026 earnings guidance for the fiscal year.

📉 Same-store cash NOI growth was mixed, rising in outpatient medical and senior housing segments but declining in labs.

⚖️ The company maintained a stable net debt to Adjusted EBITDA ratio of 5.4 times as of the reporting period.

🌱 Healthpeak achieved LEED certification for a new outpatient development in the Dallas area.

📊 Major ESG indices continue to recognize the company, potentially appealing to environmentally focused investors.

🔍 Analysts currently rate the stock as a Buy with a $18.00 price target according to recent reports.

⚠️ AI analyst Spark rates DOC as Neutral due to mixed financial performance and high leverage.

📉 Technical indicators are weak, showing the stock trading below key moving averages with negative MACD.

💹 The valuation is considered pressured by an extremely high P/E ratio despite a high dividend yield.

👨‍💼 Management signals active capital deployment through recapitalizations, share repurchases, and dividend declarations.

🩺 Lab weakness and refinancing pressures are noted as potential headwinds offsetting outpatient and senior housing strength.

🏥 Healthpeak focuses on high-demand healthcare markets including outpatient facilities, lab space, and senior housing.

Bullish Signals
  • Healthpeak raised 2026 guidance after strong Q1 results.
  • Company posted net income of $0.28 per share.
  • Janus Living IPO raised approximately $880 million.
  • Strategies return value via repurchases and dividends.
  • Healthpeak earned LEED certification for a Dallas project.
  • Same-store cash NOI grew in key segments.
  • Analysts rate Healthpeak (DOC) as Buy with $18 target.
Risk Factors
  • Same-store cash NOI declined in the lab segment.
  • Stock trades at extremely high P/E with higher leverage.
  • Weaker 2025 profitability expected to pressure shares.
  • Technical indicators weak; shares below key moving averages.
  • Negative MACD signal indicates further downside risk.
Bullish Signals
  • Healthpeak Properties raised its 2026 earnings guidance following strong Q1 2026 results, signaling management's confidence in future performance.
  • The company posted net income of $0.28 per share and Adjusted FFO of $0.45 per share for the first quarter.
  • Janus Living, a majority-owned affiliate, completed an oversubscribed IPO raising approximately $880 million, reinforcing the senior housing growth platform.
  • Recent capital deployment strategies including recapitalizations, share repurchases, and dividend declarations demonstrate active efforts to return value to shareholders.
  • Healthpeak earned LEED certification for a Dallas-area outpatient development, strengthening its appeal to environmentally focused investors through a robust ESG profile.
  • Same-store cash NOI growth was positive in the outpatient medical and senior housing segments, indicating strength in high-demand areas of the portfolio.
  • Analysts maintain a Buy rating on Healthpeak Properties (DOC) with a $18.00 price target, highlighting confidence in its investment thesis.
Risk Factors
  • Same-store cash NOI declined in the lab segment, highlighting weakening dynamics within the company's diversified healthcare portfolio.
  • The stock is trading with an extremely high P/E ratio and has been pressured by higher leverage and weaker 2025 profitability.
  • Technical indicators remain weak as shares trade below key moving averages with a negative MACD signal.
  • Future earnings growth faces risks from refinancing pressure and ongoing lab weakness despite outpatient strength.
Somewhat Bullish +50

Healthpeak: Q1 Earnings Snapshot

📊 Q1 FFO hit $316.9M (45¢/share), beating analyst estimates.

💰 Net income reached $193.5M, or 28¢ per share.

📈 Revenue soared to $753M, exceeding the Street forecast.

🔮 Management raised full-year FFO guidance to 45 cents/share.

📊 Healthpeak Properties Inc. (DOC) reported first-quarter funds from operations (FFO) of $316.9 million, or 45 cents per share, beating the average analyst estimate of 43 cents per share.

💰 The company's net income for the quarter was $193.5 million, translating to 28 cents per share.

📈 Revenue totaled $753 million, which exceeded the Street forecast of $671.9 million set by three analysts surveyed by Zacks.

🏥 As a health care REIT based in Denver, Healthpeak continues to see positive performance in its key profitability metrics.

🔮 Management raised expectations for full-year funds from operations to a range of 45 cents per share.

Bullish Signals
  • Healthpeak Q1 FFO of $316.9M beat estimates.
  • Per-share earnings were 45 cents, surpassing the 43-cent consensus.
  • Revenue hit $753M, exceeding Wall Street forecasts.
  • Net income reached $193.5M, or 28 cents per share.
  • Management raised full-year FFO guidance to $1.71-$1.75.
Bullish Signals
  • Healthpeak Properties, Inc. reported funds from operations of $316.9 million in Q1, which exceeded the average analyst estimate of 43 cents per share by delivering 45 cents per share.
  • The company's revenue of $753 million significantly outpaced Wall Street forecasts, with three analysts expecting only $671.9 million.
  • Healthpeak posted net income of $193.5 million, or 28 cents per share, reflecting strong operational performance.
  • Management raised full-year funds from operations guidance to a range of $1.71 to $1.75 per share, demonstrating confidence in future results.
Risk Factors
  • No negative aspects or risks were identified in the provided article; all reported metrics exceeded analyst expectations.
Slightly Bearish -15

3 Healthcare Stocks Paying the Highest Dividends in the Sector Right Now

📉 Perrigo offers ~10% yield but carries significant performance uncertainty and recent price declines.

🏢 Healthpeak provides 7.1% monthly income with potential upside from its senior housing restructuring.

⚠️ Medical Properties Trust acts as a yield trap with cut payouts and over $2B debt due in 2027.

📊 Few U.S. healthcare stocks over $300M offer high dividends compared to adjacent REIT sectors.

📉 Perrigo offers a forward dividend yield near 10%, but this high payout reflects significant uncertainty regarding its future performance.

🛑 Despite a 23-year streak of annual dividend increases, Perrigo's stock has dropped over 87.5% in the last decade due to growth slowdowns and rising interest costs.

💰 The company is currently trading at only 5.5 times forward earnings, with recent share price gains potentially driven by takeover rumors.

🏢 Healthpeak Properties provides a forward dividend yield of 7.1% and pays monthly dividends to income-focused investors.

🔄 A strategic restructuring into Janus Living for senior housing assets may remove a conglomerate discount and unlock upside potential.

🚫 Medical Properties Trust currently presents "yield-trap" characteristics despite its stabilizing results after recent tenant bankruptcies.

📉 MPT has cut its quarterly cash dividend twice, reducing it significantly from $0.29 per share to just $0.08 per share in 2023-2024.

🏥 The REIT's dividend challenges stem primarily from the bankruptcy of Steward Health Care and ongoing financial struggles among key tenants.

💵 MPT recently raised its quarterly dividend back to $0.09 per share, suggesting it can sustain this level based on normalized funds from operations.

⚠️ Medical Properties Trust faces substantial debt risks with over $2 billion in outstanding debt scheduled to mature in 2027.

📊 Among U.S.-listed healthcare stocks with market caps above $300 million, only a handful offer a forward dividend yield exceeding 5%.

🏥 The broader healthcare sector generally lacks many high-yielding options compared to adjacent sectors like healthcare-focused REITs.

Bullish Signals
  • Perrigo has a forward dividend yield nearing 10% and boasts an impressive 23-year track record of consecutive annual dividend increases.
  • Annual dividend growth for Perrigo has averaged over 5% for the past five years, demonstrating consistent commitment to shareholder returns.
  • The stock trades at only 5.5 times forward earnings, presenting a compelling valuation opportunity if turnaround rumors materialize.
  • Shares have recently inched higher following takeover rumors that could provide significant upside potential for investors.
  • Healthpeak Properties owns over 700 healthcare-related properties across the U.S., offering exposure to outpatient facilities, medical labs, and senior housing.
  • Janus Living successfully went public in March with a nearly $1 billion IPO, creating a publicly traded subsidiary that may help unlock value and address any conglomerate discount.
  • Healthpeak Properties is a monthly dividend stock with a forward yield of 7.1%, providing regular income to investors.
  • Medical Properties Trust has recently raised its quarterly dividend to $0.09 per share after stabilizing following previous reductions.
  • The REIT normalized funds from operations came to $0.18 per share last quarter, indicating the current dividend is likely sustainable for now.
Risk Factors
  • Perrigo's forward dividend yield of nearly 10% is described as highly reflective of uncertainty regarding the company's future performance.
  • Despite a long track record, Perrigo has experienced a significant growth slowdown in recent years due to high inflation and rising interest expenses putting pressure on profitability.
  • The stock has dropped over 87.5% over the past decade, transforming Perrigo into what is generally regarded as an accidental high-yielder and a potential value trap.
  • Healthpeak Properties has a spotty dividend growth track record, casting doubt on the sustainability of its high forward dividend yield of 7.1%.
  • Medical Properties Trust exhibits strong yield-trap vibes with significant tenant-related troubles persisting after the 2024 bankruptcy of Steward Health Care.
  • During 2023 and 2024, Medical Properties Trust reduced its quarterly cash dividend twice, cutting it from $0.29 to $0.15 per share, and then again from $0.15 to just $0.08 per share.
  • Key tenants that took over leases from Steward Health Care are still facing financial challenges, posing a continued risk to the REIT's revenue stream.
  • The REIT has looming debt maturities with over $2 billion in outstanding debt coming due in 2027.
  • Medical Properties Trust's normalized funds from operations came out to just $0.18 per share last quarter, which is barely sufficient to sustain its current dividend and leaves little room for error.
Bullish +75

Key Reasons to Add Healthpeak Properties Stock to Your Portfolio Now - Zacks Investment Research

📈 Strategic focus on lab, outpatient, and senior housing assets drives portfolio growth.

💰 Strong liquidity of $2.39B supports expansion after recent IPO proceeds and debt facilities.

🏢 Significant lease wins and acquisitions reinforce position in high-barrier healthcare markets.

📉 Analyst estimates lowered despite "Buy" rating, causing recent stock decline versus industry.

🔄 Company actively recycles capital from non-core assets to enhance financial flexibility.

📈 Healthpeak Properties (DOC) is strategically positioned to capitalize on robust demand for lab assets and anticipated increases in senior citizens' healthcare spending.

💰 The company recently closed a new $400 million unsecured delayed-draw term loan facility, which enhances its liquidity and financial flexibility.

🏢 In the same month, Healthpeak monetized senior housing assets through Janus Living Inc.'s IPO, generating net proceeds of $878 million for acquisitions and corporate purposes.

🔬 Growing life expectancy and biopharma R&D growth are driving demand for lab real estate, with AI usage expected to further accelerate drug research success rates.

📝 Healthpeak secured significant lab lease agreements totaling 333,000 square feet in the fourth quarter of 2025, reflecting its ability to meet growing tenant demand.

👴 The company's Continuing Care Retirement Community (CCRC) portfolio is well-positioned for rising senior healthcare expenditures, with occupancy at 87.4% in the fourth quarter of 2025.

🔄 Healthpeak is actively repositioning its portfolio to focus on core lab, outpatient medical, and CCRC assets while recycling capital from non-core dispositions.

🏗️ In January 2026, the company acquired a leasehold interest in a Salt Lake City lab campus for approximately $68.2 million, expanding its high-barrier-to-entry market presence.

💸 Healthpeak closed outpatient medical dispositions totaling about $325 million in the fourth quarter of 2025, covering 834,000 square feet of stabilized assets.

🛡️ As of December 31, 2025, Healthpeak reported total liquidity of approximately $2.39 billion with a net debt-to-adjusted EBITDA ratio of 5.2X.

🏦 The company holds strong credit ratings of Baa1 (Stable) from Moody's and BBB+ (Stable) from S&P Global, ensuring favorable access to the debt market.

📉 Despite a Zacks Rank #2 (Buy) rating, analyst sentiment is bearish with 2026 AFFO per share estimates lowered by 5.4% over the past two months to $1.76.

📉 Stock shares of DOC have declined 2.6% over the past month, outperforming the industry growth rate of 1.3%.

🚀 Analysts suggest considering other top-ranked REIT stocks like Crown Castle Inc. (CCI) and Prologis (PLD), both carrying a Zacks Rank #2.

💡 FFO metrics are used to gauge performance in this sector, with CCI's 2026 FFO pegged at $4.43 and PLD's full-year FFO estimated at $6.14.

📊 Healthpeak's strong balance sheet and strategic acquisitions position it to leverage growth opportunities within the specialized healthcare real estate niche.

Bullish Signals
  • Healthpeak Properties is well-positioned to benefit from robust demand for lab assets and an expected rise in senior citizens' healthcare spending.
  • The company closed on a new $400 million unsecured delayed-draw term loan facility last month, significantly enhancing its liquidity and financial flexibility.
  • Healthpeak monetized senior housing assets through Janus Living, Inc.'s IPO, securing net receipts of $7.8 billion ($878 million) to fund pending acquisitions and general corporate purposes.
  • In the fourth quarter of 2025, Healthpeak executed new lab lease agreements totaling 261,000 square feet, demonstrating strong growth in its high-demand segment.
  • The company's CCRC portfolio showed an occupancy rate of 87.4% in the fourth quarter of 2025, indicating healthy demand for senior housing assets.
  • Healthpeak has a net debt-to-adjusted EBITDA ratio of only 5.2X as of Dec. 31, 2025, reflecting a conservative leverage position that facilitates bank financing.
  • The company holds strong long-term credit ratings of Baa1 from Moody's and BBB+ from S&P Global with Stable outlooks, ensuring easy access to the debt market at favorable costs.
  • Zacks maintains a Zacks Rank #2 (Buy) designation for DOC, signaling positive analyst sentiment despite recent short-term share declines.
Risk Factors
  • Analysts are bearish on Healthpeak Properties (DOC), with the Zacks Consensus Estimate for its 2026 AFFO per share lowered 5.4% over the past two months to $1.76.
  • Over the past month, shares of DOC have declined 2.6%, significantly outpacing the industry's growth of 1.3%.
Slightly Bullish +25

Healthpeak Properties Declares Monthly Common Stock Cash Dividends for the Second Quarter of 2026

📈 Dividend declared at $0.10/share quarterly, annualizing to $1.22 per share

📉 Stock down ~17% in 52 weeks as FFO guidance missed expectations

⚠️ Concerns include AFFO decline, asset sales, and Janus Living IPO uncertainty

🏢 Healthpeak Properties, Inc. (NYSE: DOC), an S&P 500 real estate investment trust, declared a monthly common stock cash dividend of $0.10167 per share for the second quarter of 2026.

💵 The quarterly dividend totals an annualized amount of $1.22 per share for stockholders of record as of the close of business on specified dates.

📅 Dividends are payable to shareholders recorded on Friday, April 17, 2026; Thursday, April 30, 2026; Monday, June 15, 2026, and Friday, June 26, 2026.

🏥 DOC owns and operates a diversified portfolio of high-quality real estate focused on healthcare discovery and delivery across the United States.

💰 The company manages outpatient medical properties, laboratory facilities, and continuing care retirement community assets.

📉 With a market capitalization of $11.4 billion, DOC stock has decreased nearly 17% over the past 52 weeks while the S&P 500 rose by a similar margin.

⚠️ Analysts project Healthpeak to report fiscal Q1 2026 FFO as Adjusted of $0.44 per share, representing a 4.4% decline from $0.46 in the prior-year quarter.

📉 Fiscal 2026 analysts forecasts for FFO as Adjusted show a projected decrease to $1.73 per share, down nearly 6% from fiscal 2025 levels of $1.84.

📈 Conversely, full-year fiscal 2027 FFO as Adjusted is anticipated to grow 2.9% year-over-year to $1.78 per share.

📉 Shares fell 2.8% following Q4 2025 results due to weak forward guidance and 2026 Nareit FFO projections below Wall Street estimates.

⚖️ Concerns regarding the company include a drop in AFFO, plans for approximately $1 billion in asset sales, and uncertainty surrounding the Janus Living IPO.

👥 Analyst consensus on DOC stock is cautiously optimistic, with 18 analysts covering the ticker showing seven "Strong Buy," two "Moderate Buy," and nine "Hold" ratings.

🎯 The average analyst price target for Healthpeak Properties is set at $19.47, suggesting potential upside of approximately 18.5% from current trading levels.

Bullish Signals
  • $0.10167/share Q2 2026 dividend declared, $1.22 annualized
  • Met or beat Wall Street estimates in last four quarters
  • Analysts forecast FFO growth of 2.9% YoY to $1.78/share in 2027
  • Seven of 18 analysts suggest 'Strong Buy', 18.5% upside target
  • $11.4B market cap S&P 500 fully integrated REIT
Risk Factors
  • FFO projected to drop ~6% to $1.73/share, signaling earnings pressure.
  • Stock down ~17% over 52 weeks, lagging S&P 500's same period gain.
  • Shares fell 2.8% after Q4 results; 2026 FFO below 2025 levels.
  • AFFO anticipated to drop from $0.44 to $0.40 year-over-year.
  • $1B asset sales planned, potentially impacting portfolio stability and growth.
  • Janus Living IPO uncertainty adds downside risk and operational distraction.
Bullish Signals
  • Healthpeak Properties declared a monthly common stock cash dividend of $0.10167 per share for the second quarter of 2026, annualizing to $1.22 per share.
  • The company has surpassed or met Wall Street's bottom-line estimates in the last four quarterly reports, demonstrating consistent performance relative to analyst expectations.
  • Analysts forecast FFO as Adjusted to grow 2.9% year-over-year to $1.78 per share in fiscal 2027, indicating a positive growth trajectory ahead of current declines.
  • Among 18 analysts covering the stock, seven suggest a 'Strong Buy' rating and the average price target implies a potential upside of 18.5% from current levels.
  • Healthpeak Properties is a fully integrated REIT and S&P 500 company with a market cap of $11.4 billion, managing a diversified portfolio across outpatient medical, lab, and continuing care retirement community properties.
Risk Factors
  • Analysts project DOC's FFO as Adjusted for fiscal 2026 will decline nearly 6% to $1.73 per share, down from $1.84 in fiscal 2025, indicating potential earnings pressure despite recent revenue growth expectations.
  • The stock has decreased nearly 17% over the past 52 weeks, significantly lagging behind the broader S&P 500 Index's nearly 17% gain during the same period, suggesting investor concerns about the company's relative performance.
  • Following Q4 2025 results on Feb. 2, shares fell 2.8% due to weak forward guidance with 2026 Nareit FFO projected at $1.70 per share, which is below its 2025 level of $1.81.
  • AFFO is anticipated to drop to $0.40 from $0.44 year-over-year, raising concerns about the quality and sustainability of earnings growth.
  • Heavy capital recycling plans are underway, including approximately $1 billion in asset sales which could impact the company's portfolio stability and future growth prospects.
  • Uncertainty surrounding the Janus Living IPO adds further downside risk and potential operational distraction for Healthpeak Properties.
Slightly Bullish +25

Assessing Healthpeak Properties (DOC) Valuation After Recent Share Price Weakness

📉 Shares fell 5.38% recently but trade at a 48% discount to fair value.

🏥 Concentrated portfolio targets outpatient centers, labs, and senior housing in tight supply markets.

⚠️ Valuation weighs strong re-leasing potential against biotech stress and oversupply risks.

📉 Healthpeak Properties (DOC) shares fell 5.38% over the last 7 days and underperformed with an 11.20% total shareholder loss over the past year.

💰 The current share price of US$16.70 sits below a calculated fair value estimate of approximately US$20.17, suggesting a potential 48% discount to intrinsic value.

🏥 The stock holds a concentrated portfolio in healthcare real estate, specifically focused on outpatient centers, labs, and senior housing markets.

📈 Supply constraints in key markets like Boston and San Diego are tightening space, which supports strong re-leasing spreads and rent growth potential.

💡 Investment thesis relies on measured revenue growth, improved margins, and a future earnings multiple that prices in cash flows from high-quality assets.

⚠️ Risks to the valuation include biotech credit stress and potential oversupply in major healthcare hubs like Boston or San Diego.

📊 Analyst targets are currently priced 19% higher than the last close, indicating the market may already anticipate some future growth.

🔍 Simply Wall St analysis frames the debate around how much of Healthpeak's healthcare real estate story is already reflected in its current stock price.

💼 Investors are advised to weigh the rewards of re-leasing spreads against warning signs regarding biotech sector instability.

🌐 The article suggests this could be a mispriced REIT or one where growth expectations are fully accounted for in the valuation.

⚖️ Readers are encouraged to evaluate 3 key rewards and 4 important warning signs before making investment decisions based on the mixed signals.

Bullish Signals
  • Healthpeak Properties currently trades at a significant discount of 48% to its calculated intrinsic value estimate of $20.17 per share, suggesting potential upside.
  • The stock is also trading 19% below current analyst target prices, indicating the market may be undervaluing the company's healthcare real estate assets.
  • Supply constraints in key outpatient and life sciences markets are tightening available space due to lower new construction over the past two decades.
  • Healthpeak's concentrated, high-quality portfolio is well-positioned to benefit from robust re-leasing spreads supporting stronger net operating income and rent growth.
  • The company projects measured revenue growth alongside firmer margins based on a mix of outpatient, lab, and senior housing cash flows.
Risk Factors
  • The stock has experienced significant downside pressure with a 7-day decline of 5.38% and a 1-year total shareholder return loss of 11.20%, indicating fading short-term momentum.
  • Healthpeak Properties currently trades at $16.70, which is down significantly from its implied fair value estimate of $20.17, raising questions about market skepticism regarding future growth.
  • The investment thesis relies on lab tenants and key markets holding up, but biotech credit stress poses a direct threat to the stability of healthcare real estate occupancy and rent collection.
  • Potential oversupply in critical hubs like Boston or San Diego could quickly weaken the company's core narrative and negatively impact net operating income.
  • Analyst forecasts indicate a 19% gap between the current share price and analyst targets, suggesting market expectations may be overly pessimistic or that the company has underestimated risks.
  • The valuation analysis admits that it does not factor in the latest price-sensitive company announcements or qualitative material, which could introduce unexpected downside volatility.
Neutral 0

Healthpeak Properties (NYSE:DOC) Focuses On Flexibility As S&P 500 Futures React

🏛️ Healthpeak Properties invests in outpatient medical real estate assets.

💼 The company prioritizes operational flexibility to adapt to market conditions.

🔒 Full access requires logging in or registering on Kalkine Media.

📞 Registration allows representatives to contact you regarding marketing offers.

🏛️ Healthpeak Properties is a real estate trust focused on outpatient medical assets within the healthcare real estate sector.

💼 The company emphasizes operational flexibility to adapt to current market conditions and S&P 500 futures performance.

🔒 Access to the full article content requires logging in, creating a free account, or completing a registration form on Kalkine Media.

📞 By registering for access, users consent to contact from Kalkine representatives regarding marketing offers via email or phone.

🕰️ The article was published on March 24, 2026 at 02:22 PM PDT.

Somewhat Bearish -25

Healthpeak Properties Stock: Is DOC Underperforming the Real Estate Sector?

🏢 DOC is a $11.9B healthcare REIT focusing on life sciences and senior housing.

📉 Stock has fallen 16.9% from highs due to rate hikes and sector weakness.

🚀 Recent outperformance contrasts with broader underperformance relative to the real estate sector.

🏢 Healthpeak Properties (DOC) is a healthcare-focused REIT with a $11.9 billion market cap, owning properties like life sciences campuses and senior housing.

⚖️ The company is classified as a large-cap stock ($10B+) and emphasizes disciplined execution to support long-term growth.

📉 DOC stock is currently down 16.9% from its 52-week high of $20.52 reached in March 2025.

🚀 Over the past three months, DOC gained 6.6%, outperforming the Real Estate Select Sector SPDR Fund (XLRE).

📉 However, over the past six months, DOC slumped 7.7% and lagged XLRE’s 3% decline.

📉 Over the past 52 weeks, DOC plunged 16.2%, significantly underperforming XLRE's 3.2% decrease.

📈 The stock trades above its 50-day moving average since mid-February but remains below the 200-day moving average.

💸 Stock declines over the past year are attributed to rising interest rates increasing borrowing costs and reducing investor appetite for REITs.

🧬 Transition toward life sciences properties has introduced leasing and reinvestment risks alongside slower leasing activity.

⚠️ Broader real estate sector weakness and financial pressures among biotech tenants have dampened growth expectations.

🐢 DOC has substantially lagged behind peer Omega Healthcare Investors (OHI), which gained 19.1% over the past year.

📊 Out of 18 analysts covering the stock, the consensus rating is a "Moderate Buy" with a mean price target of $19.47.

💰 The mean price target of $19.47 indicates a 14.2% upside potential from current levels.

⚡ The article title questions if DOC is underperforming the real estate sector, though recent three-month data shows outperformance.

🛑 Several unrelated headlines about Micron, Delta Airlines, and Iran were included in the text but do not relate to Healthpeak Properties.

Bullish Signals
  • Healthpeak Properties (DOC) has outperformed the Real Estate Select Sector SPDR Fund (XLRE) by gaining 6.6% over the past three months while XLRE rose marginally during the same period.
  • Despite a recent stock decline, the company maintains a market cap of around $11.9 billion and is classified as a large-cap stock with a disciplined execution strategy supporting long-term growth.
  • Among the 18 analysts covering DOC stock, the consensus rating is a 'Moderate Buy' with a mean price target of $19.47, indicating approximately 14.2% upside potential from current levels.
Risk Factors
  • Healthpeak Properties stock has slumped 7.7% over the past six months and plunged 16.2% over the past 52 weeks, significantly underperforming the Real Estate Select Sector SPDR Fund's (XLRE) decline of only 3.2% during the same period.
  • The REIT is currently down by 16.9% from its 52-week high of $20.52 reached in March 2025, indicating sustained investor selling pressure and bearish sentiment.
  • Healthpeak stock has substantially lagged behind competitor Omega Healthcare Investors, Inc.'s (OHI) performance, which recorded a 19.1% surge over the past year compared to DOC's decline.
  • Rising interest rates are weighing heavily on REIT valuations by increasing borrowing costs and reducing investor appetite for income-focused assets.
  • The company's transition toward life sciences properties has introduced leasing and reinvestment risks, particularly with slower leasing activity in key lab campuses.
  • Broader weakness in the real estate sector and financial pressures among biotech tenants are dampening growth expectations for Healthpeak Properties.